Alice C. Fan

Medical oncologist, Lymphoma specialist, Urologic specialist

Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center

Lymphoma Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Urologic Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: Brown University - School of Medicine (2001) RI

Fellowship: Stanford University Medical Center (2006) CA

Board Certification: Medical Oncology, American Board of Internal Medicine (2004)

Board Certification: Internal Medicine, American Board of Internal Medicine (2001)

Internship: Brown University - School of Medicine (1999) RI

Medical Education: Albany Medical Center (1998) NY

B.A., Harvard College, Biophysics (1994)

Honors & Awards

R21: Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal cell carcinoma, NIH/NCI (August 2012-July 2014)

K23 Career Development Award, NIH/NCI (July 2010-June 2015)

TRAM Renewal Grant: Development of blood biomarkers for diagnosis and monitoring of kidney cancer, Stanford Department of Medicine (October 2012-August 2013)

Translational Research and Applied Medicine Program (TRAM) Pilot Grant, Stanford Department of Medicine (October 2011-September 2012)

Developmental Cancer Research Award, Stanford Cancer Institute (September 2011-August 2012)

Special Fellow in Clinical Research, Leukemia and Lymphoma Society (July 2006-June 2009)

Research Fellowship, Lymphoma Research Foundation (July 2004-June 2006)

Dean's Fellowship, Stanford School of Medicine (April 2004- March 2005)

Administrative Appointments

Member, Stanford Lymphoma Disease Management Group (2005 - Present)

Founding Advisor, Stanford Association for Multidisciplinary Medicine and Science (2008 - Present)

Co-Director, Stanford Nanopro1000 Instrument for Nano-scale protein detection (2008 - Present)

Associate Member, Stanford Cancer Institute Molecular Therapeutics Program (2008 - Present)

Clinical Mentor, Stanford Molecular Imaging Scholars Program (2010 - Present)

Research Mentor, NIH/NIDDK Short term education program for under-represented persons (2011 - 2011)

Inteviewer, Stanford School of Medicine Internal Medicine Residency (2011 - Present)

Member, Stanford Kidney Cancer Research Group (2011 - Present)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na
Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., & Greenberg, P. L. (2012). Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. LEUKEMIA RESEARCH, 36(1), 98-103.

"Picolog," a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo
DeChristopher, B. A., Fan, A. C., Felsher, D. W., & Wender, P. A. (2012). "Picolog," a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo. ONCOTARGET, 3(1), 58-66.

Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens
Fan, A. C., Deb-Basu, D., Orban, M. W., Gotlib, J. R., Natkunam, Y., & Felsher, D. W. (2009). Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. NATURE MEDICINE, 15(5), 566-571.

Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy
Liu, Z., Fan, A. C., Rakhra, K., Sherlock, S., Goodwin, A., & Dai, H. (2009). Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 48(41), 7668-7672.

A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice
Fan, A. C., Goldrick, M. M., Ho, J., Liang, Y., Bachireddy, P., & Felsher, D. W. (2008). A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. MOLECULAR CANCER, 7.

Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas
Tran, P. T., Fan, A. C., Bendapudi, P. K., Koh, S., Komatsubara, K., & Felsher, D. W. (2008). Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas. PLOS ONE, 3(5).

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells
Beurlet, S., Omidvar, N., Gorombei, P., Krief, P., Le Pogam, C., & Padua, R. A. (2013). BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. BLOOD, 122(16), 2864-2876.

A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide
Fan-Minogue, H., Bodapati, S., Solow-Cordero, D., Fan, A., Paulmurugan, R., & Gambhir, S. S. (2013). A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide. MOLECULAR CANCER THERAPEUTICS, 12(9), 1896-1905.

Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C.
To, C. A., Hsieh, R. W., McClellan, J. S., Howard, W., Fischbein, N. J., & Fan, A. C. (2012). Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C. BMJ case reports, 2012.

Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells
Contag, C. H., Sikorski, R., Negrin, R. S., Schmidt, T., Fan, A. C., & Thorne, S. H. (2010). Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells. CANCER RESEARCH, 70(23), 9837-9845.

CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., & Felsher, D. W. (2010). CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation. CANCER CELL, 18(5), 485-498.

Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds
Kampa, K. M., Acoba, J. D., Chen, D., Gay, J., Lee, H., & Lopez, C. D. (2009). Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(11), 4390-4395.

Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis
Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S., & Felsher, D. W. (2007). Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. BLOOD, 110(7), 2674-2684.

Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation
Wu, C.-H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007). Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 104(32), 13028-13033.

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch
Giuriato, S., Ryeom, S., Fan, A. C., Bachireddy, P., Lynch, R. C., & Felsher, D. W. (2006). Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 103(44), 16266-16271.

Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer
Giuriato, S., Rabin, K., Fan, A. C., Shachaf, C. M., & Felsher, D. W. (2004). Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. SEMINARS IN CANCER BIOLOGY, 14(1), 3-11.

p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma
King, T. C., Akerley, W., Fan, A. C., Moore, T., Mangray, S., & Safran, H. (2000). p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. CANCER, 89(4), 769-773.